CT Cadrenal Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Cadrenal Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €6.7m. The latest transaction was disclosed on 1 July 2026 (Cession). Among the most active insiders: Pham Quang X. All data is free.
€400,013
37 ops.
Sell Volume
Analyst consensus: bullish or bearish? Analysts rate Cadrenal Therapeutics, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$14.00.
Buys €81,631 €400,013 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 July 2026
All Executives49 Thresholds0 Prospectus0 Other0
Declarations 49 total
▼ Chairman and CEO · Executives · 29 Jun 2026
7,400 shares Common Stock SEC:0001213900-26-074557:0
▼ Chairman, CEO and Interim CFO · Executives · 25 Jun 2026
2,127 shares Common Stock SEC:0001213900-26-072789:0
▼ Chairman, CEO and Interim CFO · Executives · 26 Jun 2026
9,029 shares Common Stock SEC:0001213900-26-072789:1
▼ Chairman, CEO and Interim CFO · Executives · 22 Jun 2026
9,167 shares Common Stock SEC:0001213900-26-071578:0
▼ Chairman, CEO and Interim CFO · Executives · 23 Jun 2026
2,277 shares Common Stock SEC:0001213900-26-071578:1
▼ Chairman, CEO and Interim CFO · Executives · 16 Jun 2026
3,613 shares Common Stock SEC:0001213900-26-070248:0
▼ Chairman, CEO and Interim CFO · Executives · 17 Jun 2026
513 shares Common Stock SEC:0001213900-26-070248:1
● Officer · Executives · 15 Jun 2026
40,000 shares @ US$3.71 1.64% mcap 100.0% of flow Common SEC144:0001628280-26-043385
▼ Chairman, CEO and Interim CFO · Executives · 11 Jun 2026
1,462 shares Common Stock SEC:0001213900-26-068981:0
▼ Chairman, CEO and Interim CFO · Executives · 12 Jun 2026
12,996 shares Common Stock SEC:0001213900-26-068981:1
▼ Chairman, CEO and Interim CFO · Executives · 15 Jun 2026
3,666 shares Common Stock SEC:0001213900-26-068981:2
▼ Chairman, CEO and Interim CFO · Executives · 8 Jun 2026
5,893 shares Common Stock SEC:0001213900-26-067484:0
▼ Chairman, CEO and Interim CFO · Executives · 9 Jun 2026
12,992 shares Common Stock SEC:0001213900-26-067484:1
▼ Chairman, CEO and Interim CFO · Executives · 10 Jun 2026
3,500 shares Common Stock SEC:0001213900-26-067484:2
▼ CEO and Chairman · Executives · 3 Jun 2026
2,323 shares @ US$4.26 0.097% mcap 4.3% of flow Common Stock SEC:0001213900-26-065925:0
▼ CEO and Chairman · Executives · 4 Jun 2026
3,898 shares @ US$4.41 0.17% mcap 7.4% of flow Common Stock SEC:0001213900-26-065925:1
▼ CEO and Chairman · Executives · 5 Jun 2026
2,064 shares @ US$4.42 0.089% mcap 3.9% of flow Common Stock SEC:0001213900-26-065925:2
▼ CEO and Chairman · Executives · 29 May 2026
303 shares @ US$5.01 0.8% of flow Common Stock SEC:0001213900-26-064357:0
▼ CEO and Chairman · Executives · 2 Jun 2026
349 shares @ US$4.46 0.8% of flow Common Stock SEC:0001213900-26-064357:1
▼ CEO and Chairman · Executives · 11 May 2026
6,476 shares @ US$5.76 18.9% of flow Common Stock SEC:0001213900-26-062862:0
▼ CEO and Chairman · Executives · 12 May 2026
3,298 shares @ US$5.28 8.8% of flow Common Stock SEC:0001213900-26-062862:1
▼ CEO and Chairman · Executives · 28 May 2026
2,989 shares @ US$4.93 7.6% of flow Common Stock SEC:0001213900-26-062862:2
▼ CEO and Chairman · Executives · 22 May 2026
1,165 shares @ US$5.69 3.4% of flow Common Stock SEC:0001213900-26-061167:0
▼ Chief Financial Officer · Executives · 29 Dec 2025
9,933 shares @ US$6.97 36.3% of flow Common Stock SEC:0001213900-25-127110:0
▼ CEO and Chairman · Executives · 27 Oct 2025
1,315 shares @ US$13.99 9.4% of flow Common Stock SEC:0001213900-25-103146:1
25 of 49 declarations
Load more (24 remaining) About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a company focused on developing treatments for kidney diseases. It is listed on NASDAQ under the ticker CDNL.